Innovative proprietary cell therapy targets inflammation, enabling recovery of normal physiological function through allogeneic stem cells
We are present at the following events:
05th Nuremberg Wound Congress from 1st to 2nd December 2022 in Nuremberg
Our CVU-specific patient recruitment campaign site is online now.
Please visit: https://ulcus-cruris-studie.de/
We develop and commercialize innovative stem cell therapies based on the ABCB5+ mesenchymal stem cell platform
RHEACELL is a biopharmaceutical company dedicated to developing drugs using a clinical stage stem cell biotech platform addressing severe inflammation-driven diseases.
Strong clinical pipeline - we help patients suffering from severe inflammation-driven diseases with high unmet medical need (e.g. Epidermolysis Bullosa)
RHEACELL develops clinical research programs alongside world-leading experts, focusing on patients with unmet medical needs, e.g. in rare pediatric and dermatological diseases accompanied by and/or based on systemic inflammation.
National marketing authorization in Germany for novel cell therapy - we cover the full spectrum of clinical development from CMC to the market, holding marketing authorization for AMESANAR®
RHEACELL has been granted national marketing authorization in Germany (§ 4b of the German Medicinal Products Act) for its cell therapy product AMESANAR®, produced by TICEBA, for the use in patients with chronic wounds.
Off-the-shelf manufacturing process serving market needs - we apply a validated, GMP-certified and scalable allogenic manufacturing process at TICEBA
RHEACELL has exclusive access to TICEBA's stem cell manufacturing know-how: a company specializing in high through-put, off-the-shelf GMP-manufactured stem cells.
RHEACELL's cell therapy product AMESANAR® is now listed on the website of Germany's Federal Institute for Vaccines and Biomedicines (competent authority)
It is the second authorized "Somatic Cell Therapy Medicinal Product". For more information click HERE.
Pediatric Investigation Plan (PIP) approved by PDCO (EMA)
The European Medicines Agency (EMA) has approved the pediatric investigation plan for our Epidermolysis Bullosa program, bringing us one step closer to filing for marketing authorization.
World-wide exclusive patents with freedom to operate
RHEACELL is an exclusive licensee of the full ABCB5 patent portfolio from Boston Children's Hospital, a teaching affiliate of Harvard Medical School, Boston, Massachusetts. Several of these are co-owned by RHEACELL.
Founding partners: a Müller – TICEBA joint venture
The RHEACELL development program is supported by Müller Holding, shored up by investment of 60 million euros, and TICEBA, a specialist stem cell manufacturer.
Key opinion leaders as partners in clinical research programs
RHEACELL's development programs are supported by world-renowned scientists and clinicians.
R&D is the key to our success. Specializing in stem cell-based drugs and tackling this route from the outset has allowed us to bring quality and safety into a brand new research field.
Thanks to our unique stem cell technology, we are offering new healing options to patients with no alternative solution. We are dedicated to developing drugs for serious chronic and hereditary diseases that have proved refractory to conventional therapies thus far.
Day in, day out, we work passionately and steadfastly on innovative stem cell therapies for inflammatory and degenerative diseases. We discover new pathways by researching in greater depth, thinking ahead, checking and rechecking, and by putting into practice the knowledge we have gained across the globe. We know only too well that research is only as good as the process used to implement it. And progress is achievable only if it is delivered to patients via a systematic, swift and safe delivery system. This is what drives us – every single day.